Antipsychotics · First-Generation (Typical)

Fluphenazine

Brand: Prolixin, Prolixin Decanoate (LAI)

First-generation (typical) antipsychotic, phenothiazine, piperazine subclass

11 cards

Want adaptive tracking?

Create a free account and every review is tracked with spaced repetition. Cards you struggle with come back sooner, and your weak areas surface automatically.

Create free account →

Card Topics

core (1)dosing (1)risk (3)trap (2)monitoring (2)population (1)interaction (1)

All Cards

1.Fluphenazine: potency, formulations, and primary use case.

2.Fluphenazine decanoate: injection interval and site.

3.A patient on fluphenazine decanoate develops NMS. What makes management harder than with oral antipsychotics?

4.Patient on fluphenazine decanoate develops acute dystonia mid-cycle. Management?

5.Can you start fluphenazine decanoate without a prior oral trial?

6.Monitoring for chronic fluphenazine (same as haloperidol).

7.Patient misses a fluphenazine decanoate injection by 6 weeks. What's the risk?

8.When can you assess therapeutic response after starting fluphenazine decanoate?

9.When is fluphenazine decanoate still chosen over SGA LAIs?

10.Injection site reactions with fluphenazine decanoate.

11.CYP interactions with fluphenazine.

Want the full clinical reference for this medication?

Read the Fluphenazine reference page →